It also slows gastrointestinal motility, meaning that gastric (stomach) emptying is slowed down, and food will move through the GI tract more slowly
Statements from the FDA About Ozempic On October 2, 2024, the FDA issued a postmarket safety information statement about concerns with unapproved versions of GLP-1 receptor agonists used for weight loss
A larger percentage of adults receiving orforglipron achieved weight loss of at least 5%, 10%, 15% and 20% vs
Monitoring is a core part of safe and effective GLP-1 therapy
and Teresa Lozano Long School of Medicine at UT San Antonio
Other AEs reported with SGLT2i use include osmotic diuresis-related events and volume depletion-related hypotension, the latter of which tends to be more common in older adults, people with an eGFR of 3060 mL/min/1.73 m 2 , and in those taking loop diuretics [4]